SCHEMBL5359692

SCHEMBL5359692

COc1ccc2nc(NCCNc3nc4ccccc4n4c(=O)[nH]nc34)sc2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 2/20 0.55
CYP1A2 P05177 1/20 0.51
CYP2C19 P33261 1/20 0.51
BCHE P06276 1/20 0.45
ACHE P22303 1/20 0.45
QPCT Q16769 1/20 0.45
RAB9A P51151 6/20 0.45
CD274 Q9NZQ7 1/20 0.45
MAPT P10636 6/20 0.44
NPC1 O15118 5/20 0.44
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
NFKB1 P19838 3/20 0.44
NFKB2 Q00653 3/20 0.44
RELA Q04206 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
GFER P55789 1/20 0.44
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 1/20 0.44
GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5356501 0.81 ADORA1 (0.52) ADORA1CYP1A2CYP2C19RAB9AMAPT
SCHEMBL5368059 0.81 ADORA1 (0.52) ADORA1CYP1A2CYP2C19QPCTRAB9A
SCHEMBL5355187 0.81 ADORA1 (0.52) ADORA1CYP1A2CYP2C19QPCTRAB9A
SCHEMBL5408086 0.71 ADORA1 (0.85) ADORA1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL21814758 0.70 QPCT (0.63) CYP1A2CYP2C19BCHEACHEQPCT
SCHEMBL12963106 0.69 RAB9A (0.63) CYP1A2CYP2C19BCHEACHEQPCT
SCHEMBL5353863 0.69 ADORA1 (0.56) ADORA1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL27815206 0.69 RAB9A (0.81) CYP1A2CYP2C19BCHEACHERAB9A
SCHEMBL3523483 0.68 NPC1 (0.41) ADORA1CYP1A2CYP2C19QPCTRAB9A
SCHEMBL2759560 0.67 RAB9A (0.65) CYP1A2CYP2C19QPCTRAB9ACD274

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202245-B2 Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines PFIZER INC. (US) 2007-04-10 US claimed
EP-1613629-A1 SUBSTITUTED 4-AMINO 1,2,4 TRIAZOLO 4,3-A QUINOXALINES Pfizer Products Inc. (US) 2006-01-11 EP claimed
WO-2004085439-A1 SUBSTITUTED 4-AMINO[1,2,4]TRIAZOLO[4,3-A]QUINOXALINES PFIZER PRODUCTS INC. (US) 2004-10-07 WO claimed
US-20040192698-A1 Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines PFIZER INC. 2004-09-30 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192698-A1 Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines CYP4B1, CYP3A4, CYP1B1 ADORA1 12/4885CYP1A2 6/4885CYP2C19 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.